Galmed Pharmaceuticals

Company Overview

Snapshot

Founded in January 2000, Galmed Pharmaceuticals operates with 1–10 employees. The company has raised a total of $150.3M across 5 funding rounds. In May 2026, Galmed Pharmaceuticals announced results from a first-in-man pharmacokinetics study of an oral formulation of Aramchol Meglumine, demonstrating a significant increase in bioavailability.

Business overview

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for liver, metabolic, and inflammatory diseases. Its core product, Aramchol, is a drug candidate for the treatment of NASH and fibrosis, currently undergoing a Phase 3 registrational study. The company also collaborates with the Hebrew University on Amilo-5MER, a 5 amino acid synthetic peptide, and has initiated a first-in-human study for it. Galmed Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In June 2026, Galmed Pharmaceuticals announced its intent to acquire Colospan, aiming to create a GI-focused platform targeting a $6 billion market. This strategic acquisition signals Galmed's expansion beyond its current focus on liver and metabolic diseases into the broader gastrointestinal market, indicating a significant strategic pivot and potential for market diversification and growth for investors.

Company Intelligence Q&A

What was the outcome of the first-in-man pharmacokinetics study for Aramchol Meglumine?

In May 2026, Galmed Pharmaceuticals announced that results from the first-in-man pharmacokinetics study of an oral formulation of Aramchol Meglumine (AM) showed that 400mg AM increases bioavailability by approximately 500% compared to Aramchol Free Acid (AA) 300mg.

What strategic move did Galmed Pharmaceuticals announce in June 2026?

In June 2026, Galmed Pharmaceuticals announced its plan to acquire Colospan, with the goal of establishing a GI-focused platform to target a $6 billion market.

What were the key findings from the oncology MoA studies announced in November 2025?

In November 2025, Galmed Pharmaceuticals announced top-line results from oncology MoA studies, indicating that a three-drug combination of Aramchol, Stivarga, and Metformin significantly enhanced GI tumor cell killing in both in-vivo and in-vitro models.

What significant biomarker identification was announced by Galmed Pharmaceuticals in May 2025?

In May 2025, Galmed Pharmaceuticals identified a proprietary biomarker signature for Aramchol, which the company believes unlocks multi-billion-dollar expansion potential beyond NASH.

What was the outcome of Galmed Pharmaceuticals' collaboration with Tissue Dynamics?

In May 2026, Tissue Dynamics and Galmed Pharmaceuticals announced a collaboration to develop a human-centered chronic cardiac fibrosis platform to advance Aramchol-based therapeutics.